Pharmacia & Upjohn's Rogaine Rx-to-OTC switch recommended for approval Nov. 17.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE Rx-TO-OTC SWITCH RECOMMENDED FOR APPROVAL by FDA's Nonprescription Drugs and the Dermatologic and Ophthalmic Drug Advisory Committees on Nov. 17. The joint committee voted 12 to 4 to recommend to FDA that Pharmacia & Upjohn's Rogaine (minoxidil 2%) be allowed to be sold as an over-the-counter hair regrowth treatment for men and women with androgenetic alopecia (hereditary hair loss).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC